Yes, Orthofix's core medical devices and bone growth therapy systems are FDA approved or cleared for commercial distribution and clinical use in the United States.

When discussing medical devices or orthopedic care frameworks, "Safix" (or similar variant terminology associated with casting, bandaging, or stabilization products) typically presents minimal localized risks.

In orthopedic and medical device contexts, specialized systems carrying similar names are deployed to stimulate bone healing.

The Ofix 200 Tablet is a prescription fluoroquinolone antibiotic containing 200mg of ofloxacin as its active pharmaceutical ingredient.

Prescription bone growth stimulators are high-end medical devices, with retail purchase costs or monthly commercial rental fees ranging broadly from $2,000 to over $4,000 per month depending on the specific model and treatment duration required.

The cost of an Orthofix bone growth stimulator (such as their proprietary spine or extremity therapy units) varies depending on insurance contractual agreements, Medicare fee schedules, and whether the device is rented or purchased.

The "best" bone growth stimulator is determined by a physician's prescription based on the specific type of fracture, non-union status, or spinal fusion site.

The corporate net worth or market capitalization of Orthofix Medical Inc. (NASDAQ: OFIX) fluctuates dynamically during active trading hours on the Nasdaq exchange based on share price changes and total outstanding common stock.

Wall Street equity research analysts covering Orthofix Medical Inc. (NASDAQ: OFIX) maintain a general consensus rating leaning toward a Buy.

Orthofix Medical Inc. (NASDAQ: OFIX) generates robust annual net revenues scaling in the hundreds of millions of dollars, typically reporting total yearly revenues between $700 million and $750 million.

Orthofix Medical Inc.

Orthofix Medical Inc. maintains a dedicated global workforce comprising approximately 1,300 to 1,600 employees worldwide.

Depending on the context of your inquiry, OFIX can refer to multiple distinct entities. In financial markets, OFIX is the ticker symbol for Orthofix Medical Inc.

The global orthopedic and medical device market features several massive multinational corporations competing for top market share.

Bone growth stimulators are generally considered exceptionally safe medical devices with minimal adverse side effects.

Orthofix Medical Inc. maintains its primary corporate headquarters and executive administrative offices in Lewisville, Texas, United States.

Orthofix Medical Inc.

Yes, Medicare generally covers bone growth stimulators, but coverage is strictly regulated and contingent upon meeting precise medical necessity criteria.

Clinical and scientific evidence demonstrates that Orthofix's medical devices and orthopedic systems achieve high rates of clinical efficacy when utilized according to strict manufacturer guidelines and physician instructions.

Revo Health operates as a prominent management services organization partnering with specialized healthcare practices like Twin Cities Orthopedics.

Yes, Medicare generally covers non-invasive bone growth stimulators, but authorization is strictly contingent upon meeting precise medical necessity criteria.

Clinical studies evaluating non-invasive bone growth stimulators (which utilize pulsed electromagnetic field or low-intensity ultrasound technology to promote healing in non-union fractures or spinal fusions) generally report high clinical success ra...

The President and Chief Executive Officer of Orthofix Medical Inc. is Massimo Calafiore, who also serves as a member of the company's Board of Directors.

The financial cost of an Orthofix bone growth stimulator varies substantially depending on whether the device is rented or purchased, insurance contract terms, and specific Medicare fee schedules.